Cancer Screening Test
OwnerRuth Louise Loveday, John Greenmaninventors
Life of this patent
Estimating the term…
Loading patent…
OwnerRuth Louise Loveday, John Greenmaninventors
Estimating the term…
The invention provides a cancer screening test, to identify patients having an increased likelihood of cancer, comprising the step of determining the presence or absence of members of a test group of tumour associated antigens in the blood of a patient. The test group comprises a plurality of tumour-associated antigens. Antigens of particular interest include Vascular Endothelial Growth Factor-A (VEGF A); CEA 125 (Carcinoembryonic antigen 125); Prostate Specific Antigen (PSA); CA15-3 (Cancer antigen 15-3); CA125 (Cancer Antigen 125); CYFRA21-1 (Cytokeratin-19 fragments); Soluble ectodomain of c-erbB2; CA27.29 (Cancer Antigen 27.29); IGF-I (Insulin-like growth factor-1); IGF-2 (Insulin-like growth factor-2); and IGFBP-3 (Insulin-like growth factor binding protein 3). The invention also provides an antibody-based test kit to implement the screening method.
A cancer screening test, to identify patients having an increased likelihood of cancer, comprising the step of determining the presence or absence of members of a test group of tumour associated antigens in the blood of a patient, said test group comprising a plurality of tumour associated antigens;
A cancer screening test according to any preceding claim wherein said test group comprises four or more antigens.
A cancer screening test according to any preceding claim wherein the test is to identify patients having an increased likelihood of one or more cancers selected from the group comprising:
An assay kit for carrying out the screening test of any preceding claim comprising antibodies capable of binding to each of the antigens in the test group.
Dependencies are inferred from the claim text.